Feregrino, Juan P.

National Health Service · Brigham and Women's Hospital · Harvard University · Queen Mary University of London · The Royal Free Hospital · Cancer Research UK · Dana-Farber Cancer Institute · Dana-Farber Brigham Cancer Center · Barts Cancer Institute

2 papers on CoChat

Most cited papers

Verified
Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma
Choueiri, T. K., Powles, T., Burotto, M., Escudier, B., Bourlon, M. T., Zurawski, B., Oyervides Juárez, V. M., Hsieh, J. J., Basso, U., Shah, A. Y., et al. (2021) · New England Journal of Medicine
Renal cell carcinoma treatmentCancer Immunotherapy and Biomarkers
Cited by 1,791
Verified
Preference for the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer (PHranceSCa): a randomised, open-label phase II study
O'Shaughnessy, J., Sousa, S., Cruz, J., Fallowfield, L., Auvinen, P., Pulido, C., Cvetanovic, A., Wilks, S., Ribeiro, L., Burotto, M., et al. (2021) · European Journal of Cancer
HER2/EGFR in Cancer ResearchGastric Cancer Management and Outcomes
Cited by 83

Go further with a free account

Verify every reference, keep papers in a library, and ask questions across them.

Sign up - it is free